Sionna Therapeutics achieves CFTR correction in preclinical data presentation

From GlobeNewswire: 2025-06-06 11:00:00

Sionna Therapeutics, Inc. presented preclinical data at the 48th European Cystic Fibrosis Conference demonstrating that their NBD1 stabilizers in combination with modulators enable full CFTR correction in CF models. The company has completed Phase 1 trials for SION-719 and SION-451, with plans to advance to the next stage of clinical development. Results from functional and biochemical preclinical studies show high-affinity NBD1 binding and correction of CFTR function to wild-type levels. Sionna aims to revolutionize CF treatment by developing medicines that normalize CFTR function, potentially improving clinical outcomes for CF patients.



Read more at GlobeNewswire: Sionna Therapeutics Announces Presentation of Preclinical